GRAFFINITY AND BOEHRINGER INGELHEIM PHARMACEUTICALS ENTER INTO DRUG DISCOVERY RESEARCH AGREEMENT

Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. which involves four global research sites of Boehringer Ingelheim. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of various novel small molecule hit series against multiple drug targets. BioSpace (http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20060906005907&ndmHsc=v2*A1157022000000*B1157670824000*DgroupByDate*G2*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view)